Markers of muscarinic deficit for individualized treatment in schizophrenia.
acetylcholine
antipsychotics
biomarker
muscarinic receptor
personalized medicine
psychosis
schizophrenia
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
11
2022
accepted:
20
12
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
27
1
2023
Statut:
epublish
Résumé
Recent clinical studies have shown that agonists at muscarinic acetylcholine receptors effectively reduce schizophrenia symptoms. It is thus conceivable that, for the first time, a second substance class of procholinergic antipsychotics could become established alongside the usual antidopaminergic antipsychotics. In addition, various basic science studies suggest that there may be a subgroup of schizophrenia in which hypofunction of muscarinic acetylcholine receptors is of etiological importance. This could represent a major opportunity for individualized treatment of schizophrenia if markers can be identified that predict response to procholinergic vs. antidopaminergic interventions. In this perspective, non-response to antidopaminergic antipsychotics, specific symptom patterns like visual hallucinations and strong disorganization, the presence of antimuscarinic antibodies, ERP markers such as mismatch negativity, and radiotracers are presented as possible
Identifiants
pubmed: 36699495
doi: 10.3389/fpsyt.2022.1100030
pmc: PMC9868756
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1100030Informations de copyright
Copyright © 2023 Stuke.
Déclaration de conflit d'intérêts
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nicotine Tob Res. 2019 Feb 18;21(3):349-356
pubmed: 30137618
Curr Pharm Des. 2006;12(30):3901-13
pubmed: 17073686
Ann N Y Acad Sci. 2015 May;1344:105-19
pubmed: 25752648
Nat Rev Neurosci. 2015 Sep;16(9):535-50
pubmed: 26289573
J Pharmacol Exp Ther. 2016 Nov;359(2):354-365
pubmed: 27630144
Aust N Z J Psychiatry. 2019 Nov;53(11):1059-1069
pubmed: 31347380
Brain. 2011 Dec;134(Pt 12):3435-53
pubmed: 21624926
Am J Psychiatry. 2014 Sep;171(9):949-59
pubmed: 25178752
Int J Neuropsychopharmacol. 2013 Feb;16(1):37-46
pubmed: 22338582
Neuropsychol Rev. 2005 Jun;15(2):73-95
pubmed: 16211467
Neuroimage Clin. 2018 Mar 03;18:713-719
pubmed: 29560312
Front Psychiatry. 2021 Nov 25;12:777378
pubmed: 34899430
World Psychiatry. 2017 Feb;16(1):77-89
pubmed: 28127934
Pharmaceuticals (Basel). 2021 Jun 02;14(6):
pubmed: 34199622
Psychol Med. 2021 Sep 02;:1-11
pubmed: 36315242
Hum Brain Mapp. 2022 Dec 15;43(18):5452-5464
pubmed: 35848373
Br J Psychiatry. 2014 Jul;205(1):1-3
pubmed: 24986384
Neuropharmacology. 2020 Jun 15;170:108053
pubmed: 32188568
Neuroimage. 2021 Aug 15;237:118096
pubmed: 33940149
Behav Brain Res. 2021 May 7;405:113201
pubmed: 33647377
Neuroscience. 2002;111(4):815-35
pubmed: 12031406
Psychopharmacology (Berl). 2004 Dec;177(1-2):207-16
pubmed: 15258717
Am J Psychiatry. 2003 Jan;160(1):118-27
pubmed: 12505810
Schizophr Res. 2011 Apr;127(1-3):3-13
pubmed: 21316923
Biol Psychiatry. 2011 Jul 1;70(1):28-34
pubmed: 21111401
Compr Psychiatry. 2012 Aug;53(6):674-8
pubmed: 22341649
Expert Opin Ther Targets. 2006 Aug;10(4):515-31
pubmed: 16848689
Neuropsychopharmacology. 2012 Jan;37(1):4-15
pubmed: 21956446
J Clin Psychiatry. 2011 Nov;72(11):1439-44
pubmed: 21457676
Schizophr Bull. 2009 May;35(3):509-27
pubmed: 19155345
Health Technol Assess. 2001;5(33):1-56
pubmed: 11701102
Neuroscience. 2021 Feb 21;456:106-113
pubmed: 32045628
Schizophr Bull. 2006 Oct;32(4):692-700
pubmed: 16469942
ACS Chem Neurosci. 2019 May 15;10(5):2144-2159
pubmed: 30566832
CNS Neurosci Ther. 2010 Jun;16(3):137-62
pubmed: 20370804
Psychiatry Clin Neurosci. 2019 May;73(5):204-215
pubmed: 30666759
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13674-9
pubmed: 14595031
Mol Psychiatry. 2007 Mar;12(3):232-46
pubmed: 17146471
Stat Med. 2017 Jan 15;36(1):136-196
pubmed: 27488683
J Neuroimmunol. 2014 Apr 15;269(1-2):68-75
pubmed: 24636402
Schizophr Bull. 2019 Apr 25;45(3):639-646
pubmed: 29982701
Clin Interv Aging. 2009;4:225-33
pubmed: 19554093
Trends Pharmacol Sci. 2022 Dec;43(12):1098-1112
pubmed: 36273943
Schizophr Res. 2021 Oct;236:142-155
pubmed: 34509129
Mol Psychiatry. 2009 Nov;14(11):1017-23
pubmed: 18317461
Br J Psychiatry. 2016 Nov;209(5):385-392
pubmed: 27388573
J Neurochem. 2008 Dec;107(5):1188-95
pubmed: 18957051
Neuroimage. 2001 Aug;14(2):376-82
pubmed: 11467911
Int J Neuropsychopharmacol. 2009 Feb;12(1):125-35
pubmed: 18771603
Biol Psychiatry. 2016 Jun 15;79(12):980-7
pubmed: 26444073
N Engl J Med. 2021 Feb 25;384(8):717-726
pubmed: 33626254
Elife. 2022 May 03;11:
pubmed: 35502897
Psychiatry Res. 2008 Mar 15;158(2):226-47
pubmed: 18187207
Schizophr Bull. 2018 Oct 17;44(6):1301-1311
pubmed: 29301039
Int Rev Neurobiol. 2007;78:225-46
pubmed: 17349863
J Nucl Med. 2021 Apr;62(4):553-560
pubmed: 32859711
Schizophr Bull. 2009 May;35(3):549-62
pubmed: 19325164
Trends Pharmacol Sci. 2019 Dec;40(12):1006-1020
pubmed: 31711626
Transl Psychiatry. 2013 Feb 19;3:e230
pubmed: 23423139
BMC Psychiatry. 2010 Sep 07;10:68
pubmed: 20822516
Schizophr Bull. 1998;24(2):189-202
pubmed: 9613620
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15312-7
pubmed: 11752469
Neuropsychopharmacology. 2021 May;46(6):1122-1132
pubmed: 32961543